LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | CP724714 | 0.37 | uM | LJP5 | 1 | A10 | 72 | hr | 868 | 2548 | 3486 | 0.7308 | 0.6416 |
MDA-MB-231 | CP724714 | 0.37 | uM | LJP5 | 2 | A10 | 72 | hr | 868 | 2567 | 3486 | 0.7363 | 0.6489 |
MDA-MB-231 | CP724714 | 0.37 | uM | LJP5 | 3 | A10 | 72 | hr | 868 | 2816 | 3486 | 0.8077 | 0.7440 |
MDA-MB-231 | CP466722 | 0.37 | uM | LJP5 | 1 | I10 | 72 | hr | 868 | 3382 | 3486 | 0.9701 | 0.9601 |
MDA-MB-231 | CP466722 | 0.37 | uM | LJP5 | 2 | I10 | 72 | hr | 868 | 3561 | 3486 | 1.0214 | 1.0285 |
MDA-MB-231 | CP466722 | 0.37 | uM | LJP5 | 3 | I10 | 72 | hr | 868 | 3585 | 3486 | 1.0283 | 1.0377 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 1 | A22 | 72 | hr | 868 | 2318 | 3486 | 0.6649 | 0.5538 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 2 | A22 | 72 | hr | 868 | 2372 | 3486 | 0.6804 | 0.5744 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 3 | A22 | 72 | hr | 868 | 2510 | 3486 | 0.7199 | 0.6271 |
MDA-MB-231 | Momelotinib | 0.37 | uM | LJP5 | 1 | P10 | 72 | hr | 868 | 2477 | 3486 | 0.7105 | 0.6145 |
MDA-MB-231 | Momelotinib | 0.37 | uM | LJP5 | 2 | P10 | 72 | hr | 868 | 2703 | 3486 | 0.7753 | 0.7008 |
MDA-MB-231 | Momelotinib | 0.37 | uM | LJP5 | 3 | P10 | 72 | hr | 868 | 2590 | 3486 | 0.7429 | 0.6576 |
MDA-MB-231 | Dasatinib | 0.37 | uM | LJP5 | 1 | D04 | 72 | hr | 868 | 517 | 3486 | 0.1483 | -0.1341 |
MDA-MB-231 | Dasatinib | 0.37 | uM | LJP5 | 2 | D04 | 72 | hr | 868 | 521 | 3486 | 0.1494 | -0.1326 |
MDA-MB-231 | Dasatinib | 0.37 | uM | LJP5 | 3 | D04 | 72 | hr | 868 | 451 | 3486 | 0.1294 | -0.1593 |
MDA-MB-231 | Dasatinib | 0.37 | uM | LJP6 | 1 | I04 | 72 | hr | 868 | 583 | 3486 | 0.1672 | -0.1089 |
MDA-MB-231 | Dasatinib | 0.37 | uM | LJP6 | 2 | I04 | 72 | hr | 868 | 568 | 3486 | 0.1629 | -0.1146 |
MDA-MB-231 | Dasatinib | 0.37 | uM | LJP6 | 3 | I04 | 72 | hr | 868 | 484 | 3486 | 0.1388 | -0.1467 |
MDA-MB-231 | Dovitinib | 0.37 | uM | LJP5 | 1 | E22 | 72 | hr | 868 | 1769 | 3486 | 0.5074 | 0.3441 |
MDA-MB-231 | Dovitinib | 0.37 | uM | LJP5 | 2 | E22 | 72 | hr | 868 | 2044 | 3486 | 0.5863 | 0.4491 |
MDA-MB-231 | Dovitinib | 0.37 | uM | LJP5 | 3 | E22 | 72 | hr | 868 | 1861 | 3486 | 0.5338 | 0.3792 |
MDA-MB-231 | Enzastaurin | 0.37 | uM | LJP5 | 1 | D16 | 72 | hr | 868 | 3563 | 3486 | 1.0220 | 1.0293 |
MDA-MB-231 | Enzastaurin | 0.37 | uM | LJP5 | 2 | D16 | 72 | hr | 868 | 3208 | 3486 | 0.9202 | 0.8937 |
MDA-MB-231 | Enzastaurin | 0.37 | uM | LJP5 | 3 | D16 | 72 | hr | 868 | 3656 | 3486 | 1.0486 | 1.0648 |
MDA-MB-231 | Erlotinib | 0.37 | uM | LJP5 | 1 | M22 | 72 | hr | 868 | 3017 | 3486 | 0.8654 | 0.8207 |